{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-031468","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.816241+00:00","generated_at":"2026-06-04T21:36:08.960373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Terns Pharma FY2023 net loss $90.2M; cash $263.4M; key trial data expected H2 2024","bullets":["Net loss of $21.0M in Q4 2023 and $90.2M for full year 2023, vs $15.8M and $60.3M in prior year.","Cash, equivalents and securities $263.4M at Dec 31, 2023; funding expected into 2026.","CEO Amy Burroughs appointed in Feb 2024; FDA orphan drug designation for TERN-701 (CML) in March 2024.","Phase 1 TERN-701 CARDINAL interim data and TERN-601 (GLP-1) 28-day weight loss data both expected H2 2024.","R&D spend rose to $63.5M in FY2023 (from $39.6M) as clinical programs advanced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-031468","json":"https://secwatch.observer/filing/0000950170-24-031468.json","markdown":"https://secwatch.observer/filing/0000950170-24-031468.md","text":"https://secwatch.observer/filing/0000950170-24-031468.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024031468/0000950170-24-031468-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024031468/tern-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:36:08.960373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4612531fa07ccc938d9040fb5c379f22381ba461","claim":"Terns Pharmaceuticals, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Terns Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017024031468/0000950170-24-031468-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}